Oral Baclofen Management for Multiple Sclerosis‑Related Lower‑Extremity Spasticity

Initial Assessment Before Dose Escalation

• Exclude spasticity‑exacerbating conditions such as urinary tract infection, fecal impaction, and pressure ulcers before increasing baclofen dosage. 2
• Verify that the current baclofen regimen is within the therapeutic range of 30–80 mg per day, divided into three to four doses. 1

Optimizing Non‑Pharmacologic Interventions

• Implement antispastic positioning, regular range‑of‑motion exercises, stretching, splinting, and serial casting as first‑line measures. 1
• Add physical‑therapy modalities such as functional electrical stimulation (FES) and transcutaneous electrical nerve stimulation (TENS) when needed. 1

Oral Baclofen Initiation and Titration

• Begin oral baclofen at 5–10 mg per day for naïve patients. 1
• Titrate gradually to reach a target dose of 30–80 mg per day, divided into three to four administrations. 1
• Maintain the maximum tolerated dose for 4–8 weeks before deeming the trial unsuccessful. 1

Dose Adjustments for Specific Patient Populations

• In patients with renal impairment, start at 5 mg per day and apply mandatory dose reductions because baclofen is renally cleared. 1
• For elderly individuals, use slower titration schedules due to a 2–3‑fold increase in drug half‑life. 1

Monitoring for Adverse Effects

• Observe for dose‑related side effects such as sedation, dizziness, and generalized weakness; adjust the dose promptly if these occur. 1

Alternative Oral Agents When Baclofen Is Ineffective or Intolerable

• Switch to tizanidine or dantrolene as alternative oral antispastics; they provide comparable efficacy. 3
• Tizanidine is associated with a more favorable tolerability profile, particularly less muscle weakness, compared with baclofen. 3

Management of Focal Lower‑Extremity Spasticity

• For focal spasticity that impairs gait, consider targeted botulinum toxin injections into the affected lower‑limb muscles. 1
• Evidence indicates botulinum toxin is more effective than oral baclofen for focal applications, especially ankle spasticity. 3

Intrathecal Baclofen for Severe Refractory Spasticity

• Offer intrathecal baclofen therapy to patients who remain symptomatic despite the maximum oral dose (>80 mg/day). 3
• Clinical studies report >80 % improvement in muscle tone and >65 % improvement in spasms with intrathecal baclofen. 3

Safety Considerations

Avoiding Abrupt Discontinuation

• Sudden cessation of baclofen can precipitate life‑threatening withdrawal (seizures, hallucinations, delirium, fever, tachycardia, death); therefore, taper slowly over several weeks. 1

Drug Interactions and Contraindications

• Do not combine baclofen with benzodiazepines (e.g., diazepam) during stroke or MS recovery, as this may impair neurological recovery. 2
• Baclofen may exacerbate obstructive sleep apnea by promoting upper‑airway collapse; monitor respiratory status. 3

Practical Implementation Steps